STOCK TITAN
  1. Home
  2. Sec-filings
  3. ELAB
  4. [8-K] PMGC Holdings Inc. Reports Material Event

New EL-22 muscle-loss patent broadens PMGC (Nasdaq: ELAB) pipeline

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

PMGC Holdings Inc., through its wholly owned subsidiary NorthStrive Biosciences Inc., reported that NorthStrive has filed a new U.S. patent application covering its EL-22 myostatin-engineered probiotic for human pharmaceutical use. The application (U.S. Application No. 19/655,160) focuses on formulated products, dosing regimens and protections for treating a broad range of muscle-wasting conditions, including sarcopenia, muscle disuse atrophy and certain neurological disorders. This filing builds on earlier EL-22 intellectual property aimed at muscle preservation and growth, including in patients receiving GLP-1 receptor agonist weight-loss treatments, and is intended to strengthen NorthStrive’s muscle health therapeutics portfolio.

Positive

  • None.

Negative

  • None.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Patent application U.S. Application No. 19/655,160 New EL-22 human pharmaceutical use filing
Press release date April 28, 2026 NorthStrive Biosciences EL-22 announcement
10-K reporting year Year ended December 31, 2025 Form 10-K referenced for Risk Factors
myostatin-engineered probiotic medical
"EL-22, a myostatin-engineered probiotic technology, into human pharmaceutical applications."
sarcopenia medical
"address muscle loss associated with conditions such as sarcopenia, muscle disuse atrophy,"
muscle disuse atrophy medical
"conditions such as sarcopenia, muscle disuse atrophy, and certain neurological disorders."
Muscle disuse atrophy is the loss of muscle size and strength that happens when a muscle isn’t used enough, for example after prolonged bed rest, limb immobilization, or reduced activity. Investors should care because it creates demand for medical treatments, rehabilitation services, assistive devices and therapies, and can influence healthcare spending and reimbursement trends—similar to how wear-and-tear on a car drives the market for repairs and replacement parts.
GLP-1 receptor agonists medical
"including in patients undergoing weight loss treatments such as GLP-1 receptor agonists."
GLP-1 receptor agonists are medicines that mimic a natural gut hormone to lower blood sugar and reduce appetite, often used to treat diabetes and obesity. Investors care because these drugs can drive large prescription sales, face strict regulatory approval and patent timelines, and their safety, pricing, or label changes can meaningfully affect a drug maker’s revenue much like a bestselling product or a recalled item would impact any company’s financial outlook.
muscle-wasting conditions medical
"formulations targeting a broad range of muscle-wasting conditions."
forward-looking statements regulatory
"Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements”"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
Understanding 8-K Material Events →
false 0001840563 0001840563 2026-04-28 2026-04-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): April 28, 2026

 

PMGC Holdings Inc.
(Exact name of registrant as specified in its charter)

 

Nevada   001-41875   33-2382547
(State or other jurisdiction
of incorporation)		   (Commission File Number)   (I.R.S. Employer
Identification No.)

 

c/o 120 Newport Center Drive
Newport Beach, CA		   92660
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (888) 445-4886

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.0001 par value   ELAB   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 7.01 Regulation FD Disclosure.  

 

On April 28, 2026, NorthStrive Biosciences Inc., a Delaware corporation and wholly owned subsidiary of PMGC Holdings Inc. (the “Company”) issued a press release, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information furnished pursuant to this Item 7.01, including Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
99.1   Press Release dated April 28, 2026.
104   Cover Page Interactive Data File (formatted in Inline XBRL).

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: April 28, 2026

 

PMGC Holdings, Inc.  
     
By: /s/ Graydon Bensler  
Name:   Graydon Bensler  
Title: Chief Executive Officer  

 

 

2

 

 

 

Exhibit 99.1

 

NorthStrive Biosciences Files New U.S. Patent Application for EL-22 Targeting Muscle Preservation in Humans

 

NEWPORT BEACH, Calif, April 28, 2026 (GLOBE NEWSWIRE) -- NorthStrive Biosciences Inc. (“NorthStrive” or the “Company”), a wholly owned subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB) (“PMGC”), today announced the filing of a new U.S. patent application expanding its proprietary EL-22, a myostatin-engineered probiotic technology, into human pharmaceutical applications.

 

The patent application (U.S. Application No. 19/655,160) covers the development of a formulated pharmaceutical product utilizing EL-22 for use in human patients suffering from muscle loss. The application includes protection for specific dosing regimens and formulations targeting a broad range of muscle-wasting conditions.

 

The proposed therapeutic use of EL-22 is intended to address muscle loss associated with conditions such as sarcopenia, muscle disuse atrophy, and certain neurological disorders. This filing expands NorthStrive’s intellectual property strategy, building on prior applications focused on muscle preservation and growth.

 

NorthStrive’s lead asset, EL-22, leverages a myostatin engineered probiotic approach designed to support muscle preservation and growth, including in patients undergoing weight loss treatments such as GLP-1 receptor agonists.

 

This newly filed patent application is intended to strengthen NorthStrive’s expanding intellectual property portfolio and reflects the Company’s focus on muscle health therapeutics across pharmaceutical and adjacent markets.

 

About NorthStrive Biosciences Inc.

 

NorthStrive Biosciences Inc., a PMGC Holdings Inc. company, is a biopharmaceutical company focused on the development and acquisition of cutting-edge therapeutic technologies. The Company is advancing a pipeline of assets targeting muscle preservation, metabolic health, and related conditions.

 

About PMGC Holdings Inc.

 

PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across multiple industries. PMGC is focused on building long-term shareholder value through operational excellence and disciplined capital allocation. For more information, please visit https://www.pmgcholdings.com.

 

Forward-Looking Statements

 

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “believes,” “expects,” “plans,” “potential,” “would” and “future” or similar expressions such as “look forward” are intended to identify forward-looking statements. Forward-looking statements are made as of the date of this press release and are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although PMGC believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and PMGC cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. These and other risks are described more fully in PMGC’s filings with the United States Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of PMGC’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 30, 2026, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, PMGC undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

 

IR Contact:

 

IR@pmgcholdings.com

  

Source: View Original Filing on SEC EDGAR

FAQ

What did PMGC Holdings Inc. (ELAB) announce in this 8-K filing?

PMGC’s subsidiary NorthStrive Biosciences filed a new U.S. patent application for EL-22, a myostatin-engineered probiotic technology targeting muscle preservation and growth in human patients with muscle-wasting conditions, expanding its pharmaceutical-focused intellectual property portfolio.

What does the new EL-22 patent application from NorthStrive Biosciences cover?

The patent application (U.S. Application No. 19/655,160) covers a formulated pharmaceutical product utilizing EL-22, including specific dosing regimens and formulations aimed at treating a broad range of human muscle-wasting conditions and supporting muscle preservation and growth.

Which conditions could EL-22 from PMGC’s NorthStrive potentially address?

NorthStrive’s EL-22 is intended to target muscle loss associated with sarcopenia, muscle disuse atrophy and certain neurological disorders, and may also support muscle preservation in patients undergoing weight-loss treatments such as GLP-1 receptor agonists, according to the disclosed description.

How does the new EL-22 patent application affect NorthStrive’s IP strategy?

The newly filed EL-22 patent application expands NorthStrive’s intellectual property strategy by adding human pharmaceutical uses to prior muscle preservation and growth applications, aiming to strengthen its muscle health therapeutics coverage across pharmaceutical and adjacent markets.

What is NorthStrive Biosciences’ relationship to PMGC Holdings Inc. (ELAB)?

NorthStrive Biosciences Inc. is a wholly owned subsidiary of PMGC Holdings Inc. It operates as a biopharmaceutical company advancing therapeutic technologies focused on muscle preservation, metabolic health and related conditions within PMGC’s diversified portfolio.

Filing Exhibits & Attachments

4 documents

Press Releases

Other Documents